I remember years ago we used to talk about the (ACS/CAS) “academic discount”, i.e., the industrial subsidy. I doubt that industry will care about the Elsevier boycott.  Anyway, FWIW, here is evidence of Elsevier investing in our future J (as they say in France when they dig up your highway).

 

http://www.elsevier.com/wps/find/authored_newsitem.cws_home/companynews05_02212

Elsevier announced the launch of Reaxys Xcelerate™, a premium version of Reaxys® developed in close consultation with research intensive organizations.   Reaxys Xcelerate™ further extends the capabilities of Reaxys® .

Reaxys Xcelerate™ has been designed to streamline research intensive chemistry workflows for:

Reaxys ® and Reaxys Xcelerate™ follow the same agile development process, ensuring that the two versions continue to deliver the relevant content and insights needed by research chemists. To find out more about Reaxys Xcelerate™, including the opportunity to experience the product, visit External link  www.reaxys.com/info/xcelerate.

Wendy

Dr. Wendy A. Warr

Wendy Warr & Associates

6 Berwick Court, Holmes Chapel

Cheshire, CW4 7HZ, England

Tel./Fax +44 (0)1477 533837

wendy@warr.com http://www.warr.com